Hemosol closes gap in race for human blood substitute
Article Abstract:
Hemosol Inc. claims to have closed the gap, if not already the frontrunner, in the race to bring a human blood substitute to the market. The company's two US competitors, Northfield Laboratories Inc. of Evanston, IL, and Baxter International Inc. of Deerfield, IL, have suffered setbacks. Northfield Laboratories, the apparent frontrunner, was asked by the US Food and Drug Administration to include more patients in its Phase III surgical trials. Baxter has yet to resume Phase III trials, which it suspended earlier in 1998 due to higher-than-expected mortality rates.
Comment:
Claims to have closed the gap, if not already the frontrunner, in the race to bring a human blood substitute to the market
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Aventis cancer vaccine to begin trial
Article Abstract:
A possible cancer vaccine developed by Aventis Pasteur Ltd. will begin its Phase III trial of the drug in North America.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Small Chapters investors have cause for optimism. Book merger hearing to include buyers
- Abstracts: Fed inaction hammers loonie. Alaska-Canada railway link building steam
- Abstracts: AEterna in race to treat cancer. AEterna to spin off cosmetics and nutrition arm. Biotech sector heating up
- Abstracts: Discovery could ease cancer for many. Hormone therapy raises cancer risk, researchers find. Cancer war registers steady gain
- Abstracts: Investors retreat in the face of war. Old governance habits die hard